$0.16 EPS Expected for Diplomat Pharmacy, Inc. (DPLO) This Quarter
Wall Street brokerages expect that Diplomat Pharmacy, Inc. (NYSE:DPLO) will report earnings per share (EPS) of $0.16 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Diplomat Pharmacy’s earnings, with the lowest EPS estimate coming in at $0.14 and the highest estimate coming in at $0.18. Diplomat Pharmacy posted earnings per share of $0.08 during the same quarter last year, which would indicate a positive year-over-year growth rate of 100%. The business is expected to announce its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full-year earnings of $0.84 per share for the current fiscal year, with EPS estimates ranging from $0.77 to $0.86. For the next year, analysts forecast that the firm will report earnings of $0.87 per share, with EPS estimates ranging from $0.77 to $1.03. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 earnings per share.
A number of equities research analysts recently commented on the company. BidaskClub upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th. Needham & Company LLC reiterated a “buy” rating and issued a $23.75 target price (up from $19.75) on shares of Diplomat Pharmacy in a research report on Wednesday, October 4th. Mizuho set a $16.00 target price on Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, October 10th. Finally, Leerink Swann upped their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research report on Tuesday, November 7th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Diplomat Pharmacy has an average rating of “Hold” and a consensus price target of $20.19.
In related news, Director Jeffrey G. Park acquired 3,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were acquired at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the transaction, the director now directly owns 7,640 shares in the company, valued at approximately $118,114.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Atul Kavthekar acquired 2,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were bought at an average price of $15.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares of the company’s stock, valued at $30,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 15,000 shares of company stock worth $228,780. Company insiders own 30.20% of the company’s stock.
Hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue raised its position in Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after purchasing an additional 3,833 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after buying an additional 2,794 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter worth approximately $191,000. Municipal Employees Retirement System of Michigan raised its holdings in shares of Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after buying an additional 480 shares during the period. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of Diplomat Pharmacy in the third quarter worth approximately $216,000. Institutional investors and hedge funds own 67.74% of the company’s stock.
Shares of Diplomat Pharmacy (NYSE:DPLO) opened at $16.97 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The company has a market capitalization of $1,192.88, a PE ratio of 22.49, a P/E/G ratio of 3.12 and a beta of 0.74. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $21.99.
TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/0-16-eps-expected-for-diplomat-pharmacy-inc-dplo-this-quarter/1725690.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.